Skip to main content
  • AACR Journals
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Molecular Targets Collections
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Journals
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Molecular Targets Collections
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Research Article

Bevacizumab targeting diffuse intrinsic pontine glioma: results of 89Zr-bevacizumab PET imaging in brain tumor models

Marc H.A. Jansen, Tonny Lagerweij, A Charlotte P Sewing, Danielle Johanna Vugts, Dannis G. van Vuurden, Carla F.M. Molthoff, Viola Caretti, Susanna J.E. Veringa, Naomi Petersen, Angel Montero-Carcaboso, David P. Noske, W. Peter Vandertop, Pieter Wesseling, Guus A.M.S. van Dongen, Gertjan J.L. Kaspers and Esther Hulleman
Marc H.A. Jansen
Pediatric Oncology, VU University Medical Center-Cancer Centrer Amsterdam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tonny Lagerweij
Neurosurgery, VU University Medical Center-Cancer Centrer Amsterdam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Charlotte P Sewing
Pediatric Oncology, Neuro-oncology Research Group, VU University Medical Center, Cancer Center Amsterdam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Danielle Johanna Vugts
Nuclear Medicine & PET research, VU University Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dannis G. van Vuurden
Pediatric Oncology, Neuro-oncology Research Group, VU University Medical Center, Cancer Center Amsterdam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carla F.M. Molthoff
Nuclear Medicine & PET research, UV University Medical center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Viola Caretti
Neurology, Pediatrics and Neurosurgery, Standford University Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susanna J.E. Veringa
Pediatric Oncology, Neuro-oncology Research Group, VU University Medical Center, Cancer Center Amsterdam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naomi Petersen
Pediatric Oncology, Neuro-oncology Research Group, VU University Medical Center, Cancer Center Amsterdam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angel Montero-Carcaboso
Preclinical Therapeutics and Drug Delivery Research Program, Department of Oncology, Hospital Sant Joan de Deu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David P. Noske
Neurosurgery, VU University Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. Peter Vandertop
Neurosurgery, VU University Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pieter Wesseling
Department of Pathology / Neuro-oncology Research Group, VU University Medical Center / Radboud University Medical Center Nijmegen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guus A.M.S. van Dongen
Radiology & Nuclear Medicine, VU University Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gertjan J.L. Kaspers
Pediatrics, Pediatric Hematology and Oncology, VU University Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esther Hulleman
Neurosurgery, VU University Medical Center-Cancer Centrer Amsterdam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: e.hulleman@vumc.nl
DOI: 10.1158/1535-7163.MCT-15-0558
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The role of the vascular endothelial growth factor (VEGF)-inhibitor bevacizumab in the treatment of diffuse intrinsic pontine glioma (DIPG) is unclear. We aim to study the biodistribution and uptake of zirconium-89 (89Zr)-labeled bevacizumab in DIPG mouse models. Human E98-FM,U251-FM glioma cells and HSJD-DIPG-007-FLUC primary DIPG cells were injected into the subcutis, pons, or striatum of nude mice. Tumor growth was monitored by bioluminescence imaging (BLI) and visualized by Magnetic Resonance Imaging (MRI). Seventy-two to 96 hours after 89Zr-bevacizumab injections, mice were imaged by Positron Emitting Tomography (PET) and biodistribution was analyzed ex vivo. High VEGF expression in human DIPG was confirmed in a publically available mRNA database, but no significant 89Zr-bevacizumab uptake could be detected in xenografts located in the pons and striatum at an early or late stage of the disease. The E98-FM, and to a lesser extent the U251-FM and HSJD-DIPG-007 subcutaneous tumors, showed high accumulation of 89Zr-bevacizumab. VEGF expression could not be demonstrated in the intracranial tumors by in situ hybridization (ISH), but was clearly present in the perinecrotic regions of subcutaneous E98-FM tumors. The poor uptake of 89Zr-bevacizumab in xenografts located in the brain suggests that VEGF targeting with bevacizumab has limited efficacy for diffuse infiltrative parts of glial brain tumors in mice. Translating these results to the clinic would imply that treatment with bevacizumab in DIPG patients is only justified after targeting of VEGF has been demonstrated by 89Zr-bevacizumab immuno-PET. We aim to confirm this observation in a clinical PET study with DIPG patients.

  • Received July 8, 2015.
  • Revision received May 12, 2016.
  • Accepted May 26, 2016.
  • Copyright ©2016, American Association for Cancer Research.
Next
Back to top

Published OnlineFirst June 20, 2016
doi: 10.1158/1535-7163.MCT-15-0558

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Bevacizumab targeting diffuse intrinsic pontine glioma: results of 89Zr-bevacizumab PET imaging in brain tumor models
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
Citation Tools
Bevacizumab targeting diffuse intrinsic pontine glioma: results of 89Zr-bevacizumab PET imaging in brain tumor models
Marc H.A. Jansen, Tonny Lagerweij, A Charlotte P Sewing, Danielle Johanna Vugts, Dannis G. van Vuurden, Carla F.M. Molthoff, Viola Caretti, Susanna J.E. Veringa, Naomi Petersen, Angel Montero-Carcaboso, David P. Noske, W. Peter Vandertop, Pieter Wesseling, Guus A.M.S. van Dongen, Gertjan J.L. Kaspers and Esther Hulleman
Mol Cancer Ther June 20 2016 DOI: 10.1158/1535-7163.MCT-15-0558

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Bevacizumab targeting diffuse intrinsic pontine glioma: results of 89Zr-bevacizumab PET imaging in brain tumor models
Marc H.A. Jansen, Tonny Lagerweij, A Charlotte P Sewing, Danielle Johanna Vugts, Dannis G. van Vuurden, Carla F.M. Molthoff, Viola Caretti, Susanna J.E. Veringa, Naomi Petersen, Angel Montero-Carcaboso, David P. Noske, W. Peter Vandertop, Pieter Wesseling, Guus A.M.S. van Dongen, Gertjan J.L. Kaspers and Esther Hulleman
Mol Cancer Ther June 20 2016 DOI: 10.1158/1535-7163.MCT-15-0558
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Induction of telomere damage to treat pediatric brain tumors
  • Hypersensitivity of BRCA1/2-deficient cells to APTO-253
  • MAPK reactivation facilitates resistance to FGFR inhibition
Show more Research Article
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright 2016 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement